

Marina Ferrarini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7667623/publications.pdf>

Version: 2024-02-01

52
papers

2,805
citations

218677

26
h-index

197818

49
g-index

52
all docs

52
docs citations

52
times ranked

3592
citing authors

#	ARTICLE	IF	CITATIONS
1	Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. <i>Blood</i> , 2014, 124, 483-492.	1.4	462
2	Unusual expression and localization of heat-shock proteins in human tumor cells. <i>International Journal of Cancer</i> , 1992, 51, 613-619.	5.1	417
3	Human $\gamma\delta$ T cells: a nonredundant system in the immune-surveillance against cancer. <i>Trends in Immunology</i> , 2002, 23, 14-18.	6.8	144
4	Autocrine Nitric Oxide Modulates CD95-induced Apoptosis in $\gamma\delta$ T Lymphocytes. <i>Journal of Biological Chemistry</i> , 1997, 272, 23211-23215.	3.4	102
5	Macrophages exposed to <i>Mycobacterium tuberculosis</i> release chemokines able to recruit selected leucocyte subpopulations: focus on $\gamma\delta$ cells. <i>Immunology</i> , 2003, 108, 365-374.	4.4	101
6	Selective lysis of the autologous tumor by $\gamma\delta$ TCS1+ $\gamma\delta$ tumor-infiltrating lymphocytes from human lung carcinomas. <i>European Journal of Immunology</i> , 1990, 20, 2685-2689.	2.9	97
7	Immunohistochemical evidence of a cytokine and chemokine network in three patients with Erdheim-Chester disease: Implications for pathogenesis. <i>Arthritis and Rheumatism</i> , 2006, 54, 4018-4022.	6.7	95
8	BRAF ^{V600E} -mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1596-1602.	0.9	94
9	Tumor Necrosis Factor α As a Master Regulator of Inflammation in Erdheim-Chester Disease: Rationale for the Treatment of Patients With Infliximab. <i>Journal of Clinical Oncology</i> , 2012, 30, e286-e290.	1.6	79
10	Hypoxia-inducible transcription factor β 1 alpha determines sensitivity of endothelial cells to the proteasome inhibitor bortezomib. <i>Blood</i> , 2007, 109, 2565-2570.	1.4	74
11	MICA Expressed by Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance Plasma Cells Costimulates Pamidronate-Activated $\gamma\delta$ Lymphocytes. <i>Cancer Research</i> , 2005, 65, 7502-7508.	0.9	66
12	Inherited Perforin and Fas Mutations in a Patient with Autoimmune Lymphoproliferative Syndrome and Lymphoma. <i>New England Journal of Medicine</i> , 2004, 351, 1419-1424.	27.0	65
13	Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib. <i>British Journal of Haematology</i> , 2008, 141, 494-503.	2.5	65
14	Bortezomib induces autophagic death in proliferating human endothelial cells. <i>Experimental Cell Research</i> , 2010, 316, 1010-1018.	2.6	65
15	Ex-Vivo Dynamic 3-D Culture of Human Tissues in the RCM Bioreactor Allows the Study of Multiple Myeloma Biology and Response to Therapy. <i>PLoS ONE</i> , 2013, 8, e71613.	2.5	64
16	Variations of the perforin gene in patients with autoimmunity/lymphoproliferation and defective Fas function. <i>Blood</i> , 2006, 108, 3079-3084.	1.4	63
17	Killing of Laminin Receptor-Positive Human Lung Cancers by Tumor-Infiltrating Lymphocytes Bearing $\gamma\delta$ + T-Cell Receptors. <i>Journal of the National Cancer Institute</i> , 1996, 88, 436-441.	6.3	60
18	HIF-1 α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment. <i>Blood</i> , 2016, 127, 1987-1997.	1.4	52

#	ARTICLE	IF	CITATIONS
19	Erdheim-Chester disease: report on a case and new insights on its immunopathogenesis. <i>Rheumatology</i> , 2010, 49, 1203-1206.	1.9	49
20	<i>Mycobacterium tuberculosis</i> exploits the CD95/CD95 ligand system of $\hat{I}^3\hat{I}^1$ T cells to cause apoptosis. <i>European Journal of Immunology</i> , 1998, 28, 1798-1806.	2.9	46
21	Constitutive expression of IL-12 \hat{I}^2 on human multiple myeloma cells delineates a novel therapeutic target. <i>Blood</i> , 2008, 112, 750-759.	1.4	38
22	Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment. <i>Haematologica</i> , 2018, 103, 707-716.	3.5	36
23	Heterogeneous synthetic phenotype of cloned scleroderma fibroblasts may be due to aberrant regulation in the synthesis of connective tissues. <i>Arthritis and Rheumatism</i> , 1988, 31, 1221-1229.	6.7	34
24	Distinct pattern of HSP72 and monomeric laminin receptor expression in human lung cancers infiltrated by \hat{I}^3/\hat{I}^1 T lymphocytes. <i>International Journal of Cancer</i> , 1994, 57, 486-490.	5.1	34
25	Constitutive expression of the heat shock protein 72 kDa in human melanoma cells. <i>Cancer Letters</i> , 1994, 85, 211-216.	7.2	29
26	Tocilizumab in patients with multisystem Erdheim-Chester disease. <i>Oncolmmunology</i> , 2017, 6, e1318237.	4.6	29
27	A Relapsing Inflammatory Syndrome and Active Human Herpesvirus 8 Infection. <i>New England Journal of Medicine</i> , 2005, 353, 156-163.	27.0	27
28	Chromogranin A Is Preferentially Cleaved into Proangiogenic Peptides in the Bone Marrow of Multiple Myeloma Patients. <i>Cancer Research</i> , 2016, 76, 1781-1791.	0.9	24
29	Double-edged effect of \hat{V}^39/\hat{V}^2 T lymphocytes on viral expression in an in vitro model of HIV-1/mycobacteria co-infection. <i>European Journal of Immunology</i> , 2003, 33, 252-263.	2.9	23
30	Engagement of CD30 shapes the secretion of cytokines by human \hat{I}^3/\hat{I}^1 T cells. <i>European Journal of Immunology</i> , 2000, 30, 2172-2180.	2.9	22
31	NF- \hat{I}^B Modulates Sensitivity to Apoptosis, Proinflammatory and Migratory Potential in Short- versus Long-Term Cultured Human \hat{I}^3/\hat{I}^1 Lymphocytes. <i>Journal of Immunology</i> , 2008, 181, 5857-5864.	0.8	22
32	Blockade of the Fas-triggered intracellular signaling pathway in human melanomas is circumvented by cytotoxic lymphocytes. , 1999, 81, 573-579.		19
33	Skewing of cytotoxic activity and chemokine production, but not of chemokine receptor expression, in human type-1/-2 $\hat{I}^3\hat{I}^1$ T lymphocytes. <i>European Journal of Immunology</i> , 2002, 32, 2934-2943.	2.9	19
34	miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NF \hat{I}^B -mediated inflammatory mediators. <i>Cell Communication and Signaling</i> , 2020, 18, 156.	6.5	18
35	Engagement of CD30 shapes the secretion of cytokines by human $\hat{I}^3\hat{I}^1$ T cells. <i>European Journal of Immunology</i> , 2000, 30, 2172.	2.9	18
36	Angiopoietin-2 in Bone Marrow milieu promotes Multiple Myeloma-associated angiogenesis. <i>Experimental Cell Research</i> , 2015, 330, 1-12.	2.6	17

#	ARTICLE	IF	CITATIONS
37	The fibrogenic chemokine CCL18 is associated with disease severity in Erdheim-Chester disease. <i>Oncolmmunology</i> , 2018, 7, e1440929.	4.6	17
38	TNF- α in Erdheim-Chester disease pericardial effusion promotes endothelial leakage in vitro and is neutralized by infliximab. <i>Rheumatology</i> , 2014, 53, 198-200.	1.9	16
39	CD30 ligation differentially affects CXCR4-dependent HIV-1 replication and soluble CD30 secretion in non-Hodgkin cell lines and in α T β lymphocytes. <i>European Journal of Immunology</i> , 2003, 33, 3136-3145.	2.9	15
40	Plasma Chromogranin A as a marker of cardiovascular involvement in Erdheim-Chester disease. <i>Oncolmmunology</i> , 2016, 5, e1181244.	4.6	14
41	ATR addiction in multiple myeloma: synthetic lethal approaches exploiting established therapies. <i>Haematologica</i> , 2020, 105, 2440-2447.	3.5	12
42	Purification of a glycosaminoglycan-stimulatory lymphokine from supernatants of in vitro-activated human mononuclear cells. <i>Clinical Immunology and Immunopathology</i> , 1989, 50, 122-131.	2.0	11
43	3D-Dynamic Culture Models of Multiple Myeloma. <i>Methods in Molecular Biology</i> , 2017, 1612, 177-190.	0.9	10
44	Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease. <i>Blood</i> , 2021, 138, 1554-1569.	1.4	10
45	Erdheim-Chester disease: An in vivo human model of M1 activation at the crossroad between chronic inflammation and cancer. <i>Journal of Leukocyte Biology</i> , 2020, 108, 591-599.	3.3	9
46	3D culture of Erdheim-Chester disease tissues unveils histiocyte metabolism as a new therapeutic target. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 862-864.	0.9	8
47	Innovative Models to Assess Multiple Myeloma Biology and the Impact of Drugs. , 2013, , .		5
48	3D Models as a Tool to Assess the Anti-Tumor Efficacy of Therapeutic Antibodies: Advantages and Limitations. <i>Antibodies</i> , 2022, 11, 46.	2.5	3
49	A matter of life and death: More members of the TNF receptor family join human α T β T lymphocytes. <i>European Journal of Immunology</i> , 2012, 42, 803-804.	2.9	2
50	A Novel Histiocytosis With Synovial and Skin Involvement. <i>Annals of Internal Medicine</i> , 2021, 174, 273-274.	3.9	2
51	Immunometabolic activation of macrophages leads to cytokine production in the pathogenesis of KRAS-mutated histiocytosis. <i>Rheumatology</i> , 2022, 61, e93-e96.	1.9	2
52	3D Models of Surrogate Multiple Myeloma Bone Marrow Microenvironments: Insights on Disease Pathophysiology and Patient-Specific Response to Drugs. , 0, , .		0